Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance.


Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
2019
Historique:
received: 13 01 2018
revised: 10 03 2018
accepted: 29 03 2018
pubmed: 4 4 2018
medline: 27 12 2019
entrez: 4 4 2018
Statut: ppublish

Résumé

RNAi, post-transcriptional gene silencing mechanism, could be considered as one of the most important breakthroughs and rapidly growing fields in science. Researchers are trying to use this discovery in the treatment of various diseases and cancer is one of them although there are multiple treatment procedures for treatment-resistant cancers, eradication of resistance remain as an unsolvable problem yet. The current review summarizes both transcriptional and post-transcriptional gene silencing mechanisms, and highlights mechanisms leading to drug-resistance such as, drug efflux, drug inactivation, drug target alteration, DNA damages repair, and the epithelial-mesenchymal transition, as well as the role of tumor cell heterogeneity and tumor microenvironment, involving genes in these processes. It ultimately points out the obstacles of RNAi application for in vivo treatment of diseases and progressions that have been achieved in this field.

Identifiants

pubmed: 29611475
pii: CMC-EPUB-89483
doi: 10.2174/0929867325666180403141554
doi:

Substances chimiques

ATP-Binding Cassette Transporters 0
RNA, Catalytic 0
RNA, Small Interfering 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

6282-6303

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Sanaz Naghizadeh (S)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Behzad Mansoori (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Ali Mohammadi (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Ebrahim Sakhinia (E)

Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH